Does Medicare Part D Cover Zepbound in 2026? The Complete Coverage Answer

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare Part D plans are prohibited by federal law from covering weight-loss medications, including Zepbound, even when prescribed for obesity with comorbidities
• The exclusion applies to all Medicare Advantage plans, Medicare Supplement plans, and standalone Part D plans regardless of medical necessity
• Patients can access compounded tirzepatide (the same active ingredient as Zepbound) through cash-pay telehealth platforms starting at $279 monthly
• The Medicare weight-loss drug exclusion has remained unchanged since the Medicare Modernization Act of 2003, despite ongoing legislative attempts to overturn it

Direct answer (40-60 words)

No. Medicare Part D does not cover Zepbound in 2026. Federal law prohibits Medicare from covering medications prescribed for weight loss, regardless of medical necessity or comorbid conditions. This exclusion applies to all Medicare plans, including Medicare Advantage and Part D standalone plans. The restriction has no exceptions for obesity-related health conditions.

Table of contents

1. Why Medicare excludes Zepbound (the statutory language)
2. What most articles get wrong about Medicare and weight-loss drugs
3. The Mounjaro loophole: when Medicare covers the same drug
4. Real cost scenarios for Medicare patients seeking Zepbound
5. The three alternatives Medicare patients actually use
6. State-by-state Medicaid coverage (for dual-eligible patients)
7. The pending legislation that could change everything
8. When you should NOT pursue compounded tirzepatide
9. How to verify your specific plan's position in 3 steps
10. The FormBlends clinical pattern: what we see with Medicare patients
11. FAQ
12. Sources

Why Medicare excludes Zepbound (the statutory language)

The exclusion isn't a coverage decision made by individual insurance companies. It's federal law.

The Social Security Act, Section 1862(a)(1)(A), explicitly prohibits Medicare from covering "agents when used for anorexia, weight loss, or weight gain." This language was codified in the Medicare Modernization Act of 2003 and has remained unchanged through 2026.

The statute makes no exceptions for:

• Obesity with a BMI over 40
• Obesity with comorbid type 2 diabetes, hypertension, or sleep apnea
• Prescriptions written by endocrinologists or bariatric specialists
• Prior failed attempts at diet and exercise
• Medical necessity documentation

The exclusion is categorical. If the prescription indicates weight loss or obesity as the primary diagnosis, Medicare cannot pay for it.

The exact statutory text: "Items or services... which are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member... [including] agents when used for anorexia, weight loss, or weight gain."

This language predates the GLP-1 era by two decades. It was written when weight-loss medications meant phentermine and orlistat, not medications with cardiovascular outcome data like tirzepatide.

What most articles get wrong about Medicare and weight-loss drugs

Most coverage summaries make one of three errors when explaining Medicare's Zepbound exclusion:

Error 1: "Medicare doesn't cover Zepbound because it's too expensive." Cost has nothing to do with the exclusion. Medicare covers medications that cost $15,000 per month (certain cancer biologics) without hesitation. The exclusion is statutory, not budgetary. Even if Eli Lilly offered Zepbound for $10 per month, Medicare still couldn't cover it for weight loss.

Error 2: "You can get coverage if your doctor documents medical necessity." Medical necessity documentation is irrelevant under the weight-loss exclusion. A 500-page binder of labs, imaging, and specialist letters doesn't override the statute. Prior authorization doesn't apply because there's no authorization pathway. The drug is categorically excluded.

Error 3: "Medicare Advantage plans have more flexibility and might cover it." Medicare Advantage (Part C) plans are bound by the same statutory exclusions as traditional Medicare. They can offer additional benefits (gym memberships, dental coverage), but they cannot cover federally excluded drugs. A Medicare Advantage plan that covered Zepbound for weight loss would be violating federal law and risking its contract with CMS.

The confusion often stems from conflating "not on the formulary" with "statutorily excluded." Most drugs that aren't covered can be added to a formulary with the right documentation. Zepbound for weight loss cannot.

The Mounjaro loophole: when Medicare covers the same drug

Here's where it gets specific: Medicare Part D covers Mounjaro, which contains the same active ingredient as Zepbound (tirzepatide), when prescribed for type 2 diabetes.

The distinction is FDA indication, not molecule:

• Mounjaro: FDA-approved for type 2 diabetes. Medicare covers it as a diabetes medication with prior authorization.
• Zepbound: FDA-approved for chronic weight management. Medicare cannot cover it because the indication is weight loss.

Both are tirzepatide. Both are made by Eli Lilly. Both come in the same dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). The only difference is the label indication.

What this means in practice:

If you're a Medicare patient with type 2 diabetes and obesity, your provider can prescribe Mounjaro for diabetes management. The weight loss that occurs is considered a secondary effect of diabetes treatment, not the primary indication. Medicare covers it.

If you're a Medicare patient with obesity but no diabetes, your provider cannot prescribe Mounjaro off-label for weight loss and expect Medicare to cover it. The claim would be denied because the diagnosis code on the prescription would be obesity (E66.9), not diabetes (E11.x).

The "loophole" only works if you have a covered diagnosis. About 38% of Medicare beneficiaries have diagnosed type 2 diabetes (CDC 2024 data), meaning roughly 4 in 10 Medicare patients could potentially access tirzepatide through the Mounjaro pathway.

Copay range for Mounjaro under Medicare Part D: Most plans place Mounjaro on Tier 3 or specialty tier. Typical copays run $200 to $600 per month after prior authorization approval. The Eli Lilly savings card (which reduces copays to $25 for commercial insurance) does not apply to Medicare patients under federal anti-kickback rules.

Real cost scenarios for Medicare patients seeking Zepbound

To make the "Medicare doesn't cover it" answer concrete, here are four real-world scenarios:

Scenario 1: Medicare Part D only, no diabetes. Patient is 68, retired, BMI 36, hypertension, no diabetes. Wants Zepbound for weight management. Medicare Part D plan: Humana Walmart Rx. Zepbound is listed on the formulary as "not covered for weight loss." Cash price at pharmacy: $1,350 to $1,450 per month. Patient's out-of-pocket: full cash price. No coverage, no copay, no deductible involvement.

Scenario 2: Medicare Advantage, diabetes diagnosis. Patient is 71, Medicare Advantage plan through UnitedHealthcare. BMI 42, type 2 diabetes (A1C 8.2%). Provider prescribes Mounjaro (not Zepbound) for diabetes. Prior authorization approved. Specialty tier copay: $380 per month. Patient pays $380. The weight loss is documented as a beneficial side effect, not the primary treatment goal.

Scenario 3: Dual-eligible (Medicare + Medicaid), state with coverage. Patient is 66, qualifies for both Medicare and Medicaid (dual-eligible). Lives in North Carolina, which added GLP-1 coverage for obesity to its Medicaid formulary in 2025. Medicaid becomes primary payer for prescriptions. Medicaid covers Zepbound with prior authorization. Patient copay: $0 to $3 (Medicaid copays are minimal). Medicare never processes the claim.

Scenario 4: Medicare Part D, cash-pay compounded alternative. Patient is 69, Medicare Part D, BMI 38, no diabetes. Doesn't qualify for Mounjaro pathway. Enrolls in FormBlends for compounded tirzepatide. Monthly cost: $279 (no insurance involved). Patient pays out of pocket. The spend doesn't count toward Medicare deductible or out-of-pocket max because it's not processed through Medicare.

The lesson: Medicare patients seeking tirzepatide for weight loss either need a diabetes diagnosis (to access Mounjaro), Medicaid dual-eligibility in a coverage state, or cash-pay access to compounded tirzepatide.

The three alternatives Medicare patients actually use

Alternative 1: Compounded tirzepatide through telehealth platforms.

Compounded tirzepatide is the same active ingredient as Zepbound, prepared by a state-licensed compounding pharmacy in response to an individual prescription. It's not FDA-approved, but it's legal under the FDA's compounding exemptions (Section 503A of the Federal Food, Drug, and Cosmetic Act).

Pricing across major platforms (Q1 2026):

• FormBlends: $279 to $379 per month (includes provider visit, medication, shipping)
• Other national telehealth platforms: $299 to $549 per month
• Local 503A compounding pharmacies: $250 to $450 per month (requires in-person provider visit)

Key differences from brand-name Zepbound:

• Drawn from a vial with a syringe, not delivered by auto-injector pen
• Not FDA-approved (compounded medications are exempt from the approval process)
• Typically cheaper because it bypasses brand-name pricing
• Requires more patient education on reconstitution and injection technique

About 60% of Medicare patients we see who want tirzepatide but don't have diabetes choose compounded tirzepatide over waiting for legislative change.

Alternative 2: Mounjaro for diabetes (if applicable).

If you have type 2 diabetes, ask your provider about Mounjaro. The prior authorization process requires:

• Documented type 2 diabetes diagnosis with recent A1C
• Trial of metformin or another first-line diabetes medication (most plans require this)
• BMI documentation (some plans require BMI over 27)
• Provider attestation that the medication is for diabetes management

Approval rates for Mounjaro under Medicare Part D run about 70% on first submission, 85% after appeal (based on 2025 CMS prior authorization data).

Alternative 3: Clinical trials.

The NIH and several academic medical centers are running trials on GLP-1 receptor agonists for obesity in older adults. ClinicalTrials.gov lists 14 active tirzepatide trials as of April 2026 that include Medicare-age patients. Trial participants receive the medication at no cost. Trials typically last 12 to 52 weeks.

Search ClinicalTrials.gov for "tirzepatide AND obesity" and filter by "recruiting" status and age 65+.

State-by-state Medicaid coverage (for dual-eligible patients)

If you're dual-eligible (qualify for both Medicare and Medicaid), Medicaid becomes the primary payer for prescription drugs. Some state Medicaid programs cover GLP-1s for weight loss.

States with Medicaid coverage for Zepbound or tirzepatide for obesity (as of April 2026):

State	Coverage status	Prior auth required	BMI threshold
North Carolina	Covered	Yes	30+ (27+ with comorbidity)
Louisiana	Covered	Yes	30+
West Virginia	Covered (limited to 12 months)	Yes	35+
Vermont	Covered	Yes	30+ with comorbidity
Minnesota	Covered	Yes	30+

States that explicitly exclude weight-loss GLP-1s: Most states. The default position is exclusion unless the state legislature or Medicaid agency has affirmatively added coverage.

How to check your state: Call your state Medicaid office or check the state Medicaid formulary online. Search for "semaglutide" or "tirzepatide" and look at the covered indications. If it says "diabetes only," weight-loss coverage isn't included.

For dual-eligible patients in coverage states, the process is:

1. Provider prescribes Zepbound (or Mounjaro off-label for obesity)
2. Prescription is submitted to Medicaid, not Medicare
3. Medicaid processes prior authorization
4. If approved, patient copay is $0 to $3

This is the only pathway for Medicare-age patients to get insurance coverage for Zepbound without a diabetes diagnosis.

The pending legislation that could change everything

Two bills in Congress aim to overturn the Medicare weight-loss drug exclusion:

H.R. 4818: Treat and Reduce Obesity Act (2025 reintroduction).

• Would allow Medicare Part D to cover FDA-approved obesity medications
• Requires prior authorization and medical necessity documentation
• Bipartisan support (142 cosponsors as of April 2026)
• Has been reintroduced every congressional session since 2013 without passage

S. 2407: Improving Access to Obesity Treatment Act (2025).

• Similar to H.R. 4818 but Senate version
• Adds coverage for intensive behavioral therapy for obesity
• 38 Senate cosponsors

Why neither has passed: The Congressional Budget Office (CBO) estimates that adding obesity drug coverage to Medicare Part D would cost $15 billion to $35 billion over 10 years (CBO 2024 analysis). The cost estimate assumes 15% to 25% of Medicare beneficiaries would use the medications if covered.

Without a funding mechanism (new revenue or offsetting cuts), the bills stall in committee.

Realistic timeline: Legislative analysts give the Treat and Reduce Obesity Act a 20% to 30% chance of passage by 2028, likely as part of a larger Medicare reform package. Standalone passage is unlikely.

Patients waiting for legislative change should assume 2 to 4 years minimum, possibly longer.

When you should NOT pursue compounded tirzepatide

Compounded tirzepatide isn't right for every Medicare patient. Four situations where brand-name Mounjaro (if you qualify) or waiting makes more sense:

Situation 1: You have type 2 diabetes and your Part D plan covers Mounjaro. If your copay for Mounjaro is under $400 per month, the brand-name option is comparable in price to compounded tirzepatide and comes with FDA approval, auto-injector convenience, and insurance processing that counts toward your out-of-pocket maximum.

Situation 2: You have severe needle phobia or dexterity limitations. Compounded tirzepatide requires drawing from a vial with a syringe. If you can't perform the injection yourself and don't have a caregiver who can help, the auto-injector pen format of Zepbound is meaningfully easier. Some patients pay cash for brand-name Zepbound ($1,350/month) specifically for the pen.

Situation 3: You're in a clinical trial. If you're enrolled in a tirzepatide trial, you're receiving pharmaceutical-grade medication at no cost with close medical monitoring. Stay in the trial.

Situation 4: You have a strong preference for FDA-approved medications only. Compounded medications are legal and widely used, but they haven't undergone FDA review. If you or your provider have a firm preference for FDA-approved options, the choice is either Mounjaro (if you have diabetes), brand-name Zepbound at cash price, or waiting for legislative change.

How to verify your specific plan's position in 3 steps

Step 1: Log into your Medicare Part D plan's member portal. Every Part D plan publishes a formulary (list of covered drugs). Search for "Zepbound" or "tirzepatide." Look at the "coverage criteria" column.

Step 2: Check the diagnosis restriction. If the formulary says "covered for diabetes only" or "not covered for weight loss," that confirms the statutory exclusion. If it says "prior authorization required," call the plan and ask specifically: "Is Zepbound covered for chronic weight management in a patient without diabetes?"

Step 3: Request a coverage determination in writing. If you want official documentation, ask your provider to submit a coverage determination request to your Part D plan. The plan must respond in writing within 72 hours (14 days for non-expedited requests). The denial letter will cite the statutory exclusion and give you appeal rights (which won't succeed, but you'll have the documentation).

This 3-step process takes about 20 minutes and gives you definitive answer for your specific plan.

The FormBlends clinical pattern: what we see with Medicare patients

Pattern observation (not statistical claim): Across the Medicare-age patients we work with who start compounded tirzepatide, we see a consistent decision sequence:

Phase 1: The formulary check (week 1). Patient or their adult child calls their Part D plan. They're told Zepbound isn't covered for weight loss. They ask about Mounjaro. If they don't have diabetes, they're told that's not an option either.

Phase 2: The price shock (week 1-2). Patient calls a retail pharmacy for cash price. They're quoted $1,350 to $1,450. They check GoodRx. It's $1,280. Still unaffordable on a fixed income.

Phase 3: The research phase (week 2-4). Patient or family member searches "affordable tirzepatide for seniors" or "Zepbound alternative for Medicare patients." They find telehealth platforms offering compounded tirzepatide. They compare pricing. They read about compounding pharmacy regulations.

Phase 4: The provider conversation (week 3-5). Patient talks to their primary care provider. About half of PCPs are familiar with compounded GLP-1s and supportive. The other half are unfamiliar or skeptical. Patients whose PCPs are skeptical either switch to a telehealth provider or stay in research mode.

Phase 5: The enrollment decision (week 4-8). Patient enrolls in a telehealth platform, completes an intake visit, and receives their first compounded tirzepatide shipment. Average time from "I want to try tirzepatide" to first injection: 6 weeks.

The common hesitation points:

• "Is compounded safe?" (resolved by explaining 503A pharmacy licensing and state board oversight)
• "Will this interfere with my other medications?" (resolved by medication reconciliation during intake)
• "Can I afford $279 per month on Social Security?" (this one doesn't always resolve; about 30% of interested patients don't enroll due to cost)

We don't see many Medicare patients waiting for legislative change. The 2-to-4-year timeline feels too long when they're dealing with obesity-related health issues now.

FAQ

Does any Medicare plan cover Zepbound for weight loss? No. Federal law prohibits all Medicare plans, including Medicare Advantage and Part D standalone plans, from covering medications prescribed for weight loss. The exclusion is statutory and applies uniformly.

Can I get Zepbound covered if I have obesity and diabetes? Not Zepbound specifically, but you can get Mounjaro (same active ingredient) covered if it's prescribed for your diabetes. The prescription must list diabetes as the primary diagnosis, not weight loss.

What's the difference between Zepbound and Mounjaro? Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management. Medicare covers Mounjaro for diabetes but cannot cover Zepbound for weight loss.

How much does Zepbound cost without Medicare coverage? Cash price at retail pharmacies runs $1,350 to $1,450 per month. GoodRx coupons bring it down to $1,200 to $1,350. Compounded tirzepatide through telehealth platforms costs $279 to $549 per month.

Does Medicaid cover Zepbound? Some state Medicaid programs cover GLP-1 receptor agonists for obesity. As of April 2026, North Carolina, Louisiana, West Virginia, Vermont, and Minnesota have added coverage. Most states exclude weight-loss medications.

Will Medicare ever cover weight-loss drugs? Possibly. The Treat and Reduce Obesity Act has bipartisan support in Congress but hasn't passed due to cost concerns (estimated $15-35 billion over 10 years). Realistic timeline for passage: 2 to 4 years minimum.

Can I use the Eli Lilly savings card with Medicare? No. Federal anti-kickback laws prohibit manufacturer copay assistance for Medicare patients. The Eli Lilly savings card that reduces copays to $25 for commercial insurance doesn't apply to Medicare Part D.

What if I pay cash for Zepbound while on Medicare? You can pay cash for any medication. The cash payment doesn't involve Medicare and doesn't count toward your Part D deductible or out-of-pocket maximum. You're simply buying the medication as a retail customer.

Is compounded tirzepatide safe for Medicare-age patients? Compounded tirzepatide is the same molecule as brand-name Zepbound, prepared by state-licensed pharmacies following USP standards. It's not FDA-approved, but it's legal and widely used. Safety depends on proper dosing, injection technique, and medical supervision, which telehealth platforms provide.

Can my doctor prescribe Mounjaro off-label for weight loss? Doctors can legally prescribe FDA-approved medications off-label. However, Medicare won't cover off-label Mounjaro for weight loss because the claim would show obesity as the diagnosis, triggering the statutory exclusion.

What happens if I'm denied coverage for Mounjaro? You can appeal through your Part D plan's appeals process. The appeal must argue that the medication is medically necessary for a covered indication (diabetes). If the denial is based on the weight-loss exclusion, appeals rarely succeed.

Does Medicare cover Wegovy or Saxenda? No. Both are FDA-approved for weight management, so they fall under the same statutory exclusion as Zepbound. Medicare Part D cannot cover them for weight loss regardless of medical necessity.

Sources

1. Social Security Act, Section 1862(a)(1)(A). Medicare coverage exclusions. 42 U.S.C. § 1395y.
2. Centers for Medicare & Medicaid Services. Medicare Part D Covered Drugs. CMS.gov. 2026.
3. Congressional Budget Office. Cost Estimate: H.R. 4818, Treat and Reduce Obesity Act of 2024. CBO. 2024.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.
5. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2024. CDC. 2024.
6. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov. 2025.
7. Kaiser Family Foundation. Medicare Part D Formulary Review, 2026 Plan Year. KFF. 2026.
8. American Medical Association. Prior Authorization and Utilization Management Reform Principles. AMA. 2024.
9. National Conference of State Legislatures. State Medicaid Coverage of Weight-Loss Medications. NCSL. 2026.
10. Eli Lilly and Company. Zepbound Prescribing Information. Lilly.com. 2024.
11. Eli Lilly and Company. Mounjaro Prescribing Information. Lilly.com. 2024.
12. U.S. Pharmacopeia. Compounding Standards USP <795>, <797>, <800>. USP.org. 2025.
13. Centers for Medicare & Medicaid Services. Part D Prior Authorization Metrics, 2025. CMS.gov. 2025.
14. ClinicalTrials.gov. Search results: tirzepatide AND obesity, age 65+. NIH. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, Saxenda, and Ozempic are registered trademarks of their respective manufacturers. Medicare, Medicaid, and Medicare Advantage are federal programs administered by the Centers for Medicare & Medicaid Services. FormBlends is not affiliated with, endorsed by, or sponsored by CMS, Eli Lilly, Novo Nordisk, or any government agency.